268 related articles for article (PubMed ID: 32117045)
1. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.
Gadelha M; Bex M; Colao A; Pedroza García EM; Poiana C; Jimenez-Sanchez M; Yener S; Mukherjee R; Bartalotta A; Maamari R; Raverot G
Front Endocrinol (Lausanne); 2019; 10():931. PubMed ID: 32117045
[No Abstract] [Full Text] [Related]
2. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
3. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S; Murakami M; Kaneko T; Shimatsu A
Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Colao A; Bronstein MD; Brue T; De Marinis L; Fleseriu M; Guitelman M; Raverot G; Shimon I; Fleck J; Gupta P; Pedroncelli AM; Gadelha MR
Eur J Endocrinol; 2020 Jun; 182(6):583. PubMed ID: 32217809
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
14. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
Shimon I; Saeger W; Wildemberg LE; Gadelha MR
Hormones (Athens); 2017 Jan; 16(1):84-91. PubMed ID: 28500831
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M; Dreval A; Bondar I; Vagapova G; Macut D; Pokramovich YG; Molitch ME; Leonova N; Raverot G; Grineva E; Poteshkin YE; Gilgun-Sherki Y; Ludlam WH; Patou G; Haviv A; Gordon MB; Biermasz NR; Melmed S; Strasburger CJ
Lancet Diabetes Endocrinol; 2022 Feb; 10(2):102-111. PubMed ID: 34953531
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
[TBL] [Abstract][Full Text] [Related]
17. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
18. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Fleseriu M; Rusch E; Geer EB;
Endocrine; 2017 Jan; 55(1):247-255. PubMed ID: 27896545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
